Trials / Terminated
TerminatedNCT00279422
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
Detailed description
PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | visilizumab | |
| DRUG | visilizumab |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-01-19
- Last updated
- 2012-03-12
Locations
70 sites across 14 countries: United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Netherlands, Norway, Slovakia, Ukraine
Source: ClinicalTrials.gov record NCT00279422. Inclusion in this directory is not an endorsement.